A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Clinical trial NCT05090371 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05090371
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis

Start date: 2022-03-02
Primary completion: 2027-04-13
Enrollment: 136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.